Rosuvastatin should not be given with patients with acute liver diseases or unexplained persistent raised serum-aminotransferase concentrations. It should be avoided during pregnancy since there is a possibility that it could interfere with fetal sterol synthesis; there have been a few reports of congenital abnormalities associated with HMG-CoA interfere inhibitors. It should be discontinued if marked increases in serum-aminotransferase or creatinine phospokinase concentrations occur.